story of the week
[177]Lu-PSMA-617 Plus Enzalutamide for Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial
Lancet Oncol 2024 May 01;25(5)563-571, L Emmett, S Subramaniam, M Crumbaker, A Nguyen, AM Joshua, A Weickhardt, ST Lee, S Ng, RJ Francis, JC Goh, DA Pattison, TH Tan, ID Kirkwood, C Gedye, NK Rutherford, S Sandhu, AR Kumar, D Pook, S Ramdave, DP Nadebaum, M Voskoboynik, AD Redfern, W Macdonald, L Krieger, G Schembri, W Chua, P Lin, L Horvath, P Bastick, P Butler, AY Zhang, S Yip, H Thomas, A Langford, MS Hofman, M McJannett, AJ Martin, MR Stockler, ID DavisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.